TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
NCT02322281
Terminated
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated, advanced/metastatic NSCLC after failure of at least 1 previous EGFR-directed TKI and at least 1 line of platinum-containing doublet chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2019
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +79 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
NCT02583477
Completed
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/26/2019
Locations: Research Site, Rochester, New York +6 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)
NCT02124369
Terminated
Pancreatic cancer is difficult to treat, and even in a situation where an operation can be performed to remove the cancer, the disease can unfortunately come back soon afterwards. When pancreatic cancer is more advanced, the outcomes are even less positive. Recently, a large international study showed that combining a chemotherapy drug that is standard for treating pancreatic cancer, called gemcitabine with a new chemotherapy drug called Abraxane was more effective than gemcitabine alone for pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2019
Locations: Addenbrookes Hospital, Cambridge, Not set
Conditions: Pancreatic Adenocarcinoma
Register for Updates
Scheduling Nab-paclitaxel With Gemcitabine
NCT03529175
Completed
Metastatic pancreatic cancer is difficult to treat. Until recently, most patients would be offered treatment with a chemotherapy drug called gemcitabine. However, a large international trial showed that combining gemcitabine with a drug called nab-paclitaxel (or abraxane) was more effective compared with gemcitabine alone. The purpose of this study is to compare two different ways of combining gemcitabine with abraxane. Conventionally, both drugs are given on the same day via a drip into a vein... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2019
Locations: Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire +22 locations
Conditions: Pancreatic Adenocarcinoma Metastatic
Register for Updates
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
NCT02302807
Completed
This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 9... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2019
Locations: Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia +216 locations
Conditions: Bladder Cancer
Register for Updates
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer
NCT01901146
Completed
The purpose of this research study is to compare the effectiveness and safety of ABP 980 against trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/18/2019
Locations: Research Site, Brest, Not set +97 locations
Conditions: Breast Cancer
Register for Updates
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
NCT01271725
Completed
The general aim of this study is to investigate the efficacy and safety of afatinib (BIBW 2992) alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed HER2-targeted treatment in the neoadjuvant or adjuvant setting
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/15/2019
Locations: Queen Mary Hospital, Hong Kong, Not set +26 locations
Conditions: Breast Neoplasms
Register for Updates
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
NCT01881230
Completed
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/19/2019
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +139 locations
Conditions: Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer, Triple-negative Metastatic Breast Cancer, Metastatic Breast Cancer
Register for Updates
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
NCT02640755
Completed
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts: 1. Single Dose Period - will characterise the absorption, metabolism, excretion and pharmacokinetics of a single oral dose of \[14C\]AZD2014 from the body 2. Multiple Dose Period - will further assess the safety and tolerability and anti-tumour activity of multiple doses of AZD2014 when given as a monotherapy or given in combination with paclitaxel or fulvestrant.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/25/2019
Locations: Research Site, Manchester, Not set
Conditions: Solid Malignancies
Register for Updates
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
NCT01663727
Completed
This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally recurrent, or metastatic HER2-negative breast cancer. Patients will be randomized to one of two treatment arms: bevacizumab or placebo. All patients will be given an intravenous (IV) infusion of of paclitaxel (90 mg/m2) for 3 weeks during each 28-day cycle. bevacizumab or p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama +177 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
NCT00876395
Completed
The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2018
Locations: University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst., Mobile, Alabama +141 locations
Conditions: Breast Cancer
Register for Updates
Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
NCT02741856
Unknown
Research has shown that increasing the dose of radiotherapy improves outcomes in patients with lung and head and neck cancers. This study aims to see whether this is also the case for patients with tumour of the oesophagus. This trial will compare the effects of the standard dose of radiotherapy to a higher dose whilst closely monitoring the side effects. A comparison will also be made regarding the effects of the standard drugs used in chemotherapy (cisplatin and capecitabine) with an alternat... Read More
Gender:
ALL
Ages:
17 years and above
Trial Updated:
10/24/2018
Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +25 locations
Conditions: Oesophageal Cancer
Register for Updates